High Cholesterol

Clinical Trial Finder

Many patients with high cholesterol are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

A Research Study Investigating How NNC0385-0434 is Tolerated in People With or Without High Cholesterol Levels

Conditions:   Healthy Volunteers;   Hypercholesterolaemia
Interventions:   Drug: NNC0385-0434;   Drug: Placebo (NNC0385-0434)
Sponsor:   Novo Nordisk A/S
Not yet recruiting

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia

Condition:   Hypercholesterolemia
Interventions:   Drug: Alirocumab SAR236553 (REGN727);   Drug: Rosuvastatin;   Drug: Ezetimibe;   Drug: Cholestyramine;   Drug: Nicotinic acid;   Drug: Fenofibrate;   Drug: Omega-3 fatty acids;   Drug: Atorvastatin;   Drug: Simvastatin;   Drug: Fluvastatin;   Drug: Pravastatin;   Drug: Lovastatin
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Active, not recruiting

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

Condition:   Hypercholesterolaemia
Interventions:   Drug: Alirocumab SAR236553 (REGN727);   Drug: Rosuvastatin;   Drug: Atorvastatin;   Drug: Simvastatin;   Drug: Pravastatin;   Drug: Lovastatin;   Drug: Fluvastatin;   Drug: Ezetimibe;   Drug: Cholestyramine;   Drug: Nicotinic acid;   Drug: Fenofibrate;   Drug: Omega-3 fatty acids;   Drug: Placebo
Sponsors:   Sanofi;   Regeneron Pharmaceuticals

Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia

Condition:   Homozygous Familial Hypercholesterolemia
Intervention:   Drug: evinacumab
Sponsor:   Regeneron Pharmaceuticals
Enrolling by invitation

Lipid-lowering Therapies in Vietnamese Chronic Kidney Disease Population

Conditions:   Hypercholesterolemia;   Chronic Kidney Diseases
Interventions:   Drug: Simvastatin 40mg;   Drug: Ezetimibe/simvastatin 10/20 mg/day;   Drug: Ezetimibe/simvastatin 10/40 mg/day
Sponsors:   Hue University of Medicine and Pharmacy;   Università degli Studi di Sassari

Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo

Condition:   Hypercholesterolemia
Interventions:   Drug: Praluent (Alirocumab);   Drug: Placebo
Sponsors:   Regeneron Pharmaceuticals;   Sanofi
Active, not recruiting

The Genetic, Protein, and Lipid Basis of Variation in Cholesterol Efflux

Condition:   Lipid Metabolism Disorders
Sponsors:   University of Texas Southwestern Medical Center;   National Heart, Lung, and Blood Institute (NHLBI)
Enrolling by invitation

Ezetimibe (EZ)/Atorvastatin (Ator) (MK-0653C) vs. Ator in Chinese Hypercholesterolemic Participants (MK-0653C-439)

Condition:   Hypercholesterolemia
Interventions:   Combination Product: EZ 10 mg/Ator 10 mg;   Combination Product: EZ 10 mg/Ator 20 mg;   Drug: Atorvastatin;   Drug: Placebo for FDC EZ/Ator;   Drug: Placebo for atorvastatin
Sponsor:   Merck Sharp & Dohme Corp.

Ezetimibe in Patients Hypo-responsive to Statins

Conditions:   High Cholesterol;   Coronary Artery Disease
Interventions:   Drug: Ezetimibe;   Drug: Atorvastatin
Sponsors:   University of California, San Diego;   Merck Sharp & Dohme Corp.

Causes and Natural History of Dyslipidemias

Conditions:   Hypercholesterolemia;   Atherosclerosis
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)

Vascular Inflammation in Psoriasis-Ustekinumab (VIP-U)

Conditions:   Psoriasis;   Cardiovascular Disease
Interventions:   Drug: Ustekinumab;   Drug: Placebo
Sponsors:   University of Pennsylvania;   Janssen Scientific Affairs, LLC

Genetics of Obesity, Diabetes, and Heart Disease in African Diaspora Populations

Conditions:   Diabetes;   Cardiovascular Disease
Sponsor:   National Human Genome Research Institute (NHGRI)
Enrolling by invitation

Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study.

Condition:   Obsessive-Compulsive Disorder
Interventions:   Drug: Psilocybin (0.25mg/kg);   Drug: Niacin (250mg)
Sponsors:   Yale University;   Heffter Research Institute

Treatment for Non-Alcoholic Fatty Liver With Different Doses of Vitamin E

Condition:   Fatty Liver
Interventions:   Drug: Vitamin E 200 IU/d;   Drug: Vitamin E 400 IU/d;   Drug: Vitamin E 800 IU/d;   Behavioral: Diet and Exercise
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Active, not recruiting

Grape Polyphenols and Metabolic Syndrome

Condition:   Metabolic Syndrome, Protection Against
Intervention:   Dietary Supplement: Table Grape supplement
Sponsor:   Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
Not yet recruiting

Effect of Simvastatin Withdrawal on Ocular Endothelial Function

Condition:   Healthy
Interventions:   Device: Dynamic Vessel Analyzer (DVA);   Device: Laser Doppler Velocimetry (LDV);   Drug: Simvastatin;   Other: Placebo
Sponsor:   Medical University of Vienna
Not yet recruiting

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

Condition:   Dyslipidemia
Interventions:   Biological: Evolocumab;   Drug: Placebo
Sponsor:   Amgen

Post Approval Study for Treatment of Drug-resistant Adult Primary FSGS Using the LIPOSORBER® LA-15 System

Condition:   Focal Segmental Glomerulosclerosis
Intervention:   Device: LIPOSORBER® LA-15
Sponsor:   Kaneka Pharma America LLC
Not yet recruiting

Improved Cardiovascular Risk Reduction to Enhance Rural Primary Care

Conditions:   Diabetes Mellitus;   Hypertension;   Coronary Artery Disease;   Atrial Fibrillation;   Stroke
Interventions:   Other: PHCVRS Intervention;   Other: Personal Health Record
Sponsor:   Korey Kennelty

Primary Prevention Program

Condition:   Primary Prevention of Cardiovascular Disease
Intervention:   Behavioral: extended counseling
Sponsors:   National Research Center for Preventive Medicine;   The League of Clinical Research, Russia
Enrolling by invitation

Study to Evaluate the Efficacy and Safety of Belviq XR® in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years

Condition:   Obesity
Interventions:   Drug: lorcaserin hydrochloride XR;   Drug: Placebo
Sponsor:   Eisai Inc.